Show less
Hardy: Why dollar bulls may be in for a wait
John J Hardy
Yesterday at 10:43 GMT
Lambert: Stockpile decline sparks rally in Brent Crude
Clive Lambert - FuturesTechs
Yesterday at 6:43 GMT
#SaxoStrats - Buying short-dated EURJPY put
John J Hardy
Thursday at 10:11 GMT
Coleman: USDCHF upside action
Ian Coleman - First 4 Trading
Thursday at 6:14 GMT
#SaxoStrats - How to trade this copper weakness
Ole Hansen
Wednesday at 13:24 GMT
European equities bask in ECB's summer bond boost
Peter Garnry
Wednesday at 9:09 GMT
Collins: EURUSD can go lower
Wednesday at 6:20 GMT
Saxo TV / 06 May 2014 at 12:03 GMT

Buying the biotech boost

Peter Garnry

Leading Bio tech firms, have seen around thirty percent growth in the last year and prospects continue to look good, according to Saxo Bank’s Head of Equity Research, Peter Garnry.   

We’re talking about a futuristic industry, at the leading edge of research, one firm to watch is BioGen Idec Inc (BIIB:xnas), a global biotech company, which has seen around 35 percent growth in its share price over the last year. Shares are now trading around the $290.00 mark, Biogen is well known for developing Multiple Sclerosis therapies, as well as researching drugs for other auto-immune conditions.

The biotech sector has tremendous potential, according to Peter, because as the world’s population grows, so will successful companies exploring the future of drug development.    


The Saxo Bank Group entities each provide execution-only service and access to permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on or as a result of the use of the Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Show latest activity
Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail